A

Welcome to the Brand page for “A”, which is offered here for The mark consists of a stylized letter a.;pharmaceutical preparations, rna therapeutics for use in the treatment of transthyretin (ttr)-mediated amyloidosis (attr), hereditary attr amyloidosis, hepatic porphyrias, primary hyperoxaluria type 1, pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of transthyretin (ttr)-mediated amyloidosis (attr), porphyria, hereditary attr amyloidosis, hepatic porphyrias, primary hyperoxaluria type 1;color is not claimed as a feature of the mark.;.

Its status is currently believed to be active. Its class is unavailable. “A” is believed to be currently owned by “Alnylam Pharmaceuticals, Inc.”